Summary: Spatial biology approaches enabled by innovations in imaging biomarker platforms and artificial intelligence–enabled data integration and analysis provide an assessment of patient and disease heterogeneity at ever-increasing resolution. The utility of spatial biology data in accelerating drug programs, however, requires balancing exploratory discovery investigations against scalable and clinically applicable spatial biomarker analysis.

中文翻译：

---

利用空间多组学加速药物开发

摘要：通过成像生物标志物平台的创新和人工智能支持的数据集成和分析，空间生物学方法能够以不断提高的分辨率对患者和疾病异质性进行评估。然而，空间生物学数据在加速药物项目中的效用需要平衡探索性发现研究与可扩展且临床适用的空间生物标志物分析。